Clinical Trials
7 trialsNCT07005102 2026-06-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT03899155 2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06119581 2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06333951 2026-05-28
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Phase 1 Active not recruiting
NCT07252739 2026-05-26
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT03530397 2026-05-19
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Active not recruiting